INmune Bio, Inc. (NASDAQ:INMB) Short Interest Update

INmune Bio, Inc. (NASDAQ:INMB) was the recipient of a significant increase in short interest in October. As of October 15th, there was short interest totalling 2,830,000 shares, an increase of 5.6% from the September 30th total of 2,680,000 shares. Based on an average daily volume of 225,300 shares, the short-interest ratio is presently 12.6 days.

Insider Buying and Selling

In other news, CEO Raymond Joseph Tesi purchased 15,380 shares of the stock in a transaction dated Thursday, September 12th. The shares were bought at an average cost of $6.38 per share, for a total transaction of $98,124.40. Following the transaction, the chief executive officer now owns 1,554,106 shares in the company, valued at $9,915,196.28. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other INmune Bio news, CEO Raymond Joseph Tesi purchased 15,380 shares of the business’s stock in a transaction on Thursday, September 12th. The stock was bought at an average cost of $6.38 per share, with a total value of $98,124.40. Following the acquisition, the chief executive officer now owns 1,554,106 shares of the company’s stock, valued at $9,915,196.28. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO David J. Moss acquired 10,000 shares of the stock in a transaction dated Monday, September 30th. The stock was acquired at an average cost of $5.29 per share, for a total transaction of $52,900.00. Following the purchase, the chief financial officer now directly owns 1,285,869 shares in the company, valued at approximately $6,802,247.01. The trade was a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought a total of 33,070 shares of company stock valued at $200,087 over the last quarter. Corporate insiders own 35.20% of the company’s stock.

Hedge Funds Weigh In On INmune Bio

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. CVI Holdings LLC bought a new stake in shares of INmune Bio during the 2nd quarter worth about $5,260,000. Marshall Wace LLP raised its position in shares of INmune Bio by 332.1% during the second quarter. Marshall Wace LLP now owns 115,916 shares of the company’s stock valued at $1,022,000 after buying an additional 89,091 shares during the last quarter. Bank of New York Mellon Corp lifted its position in shares of INmune Bio by 124.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 58,600 shares of the company’s stock worth $517,000 after acquiring an additional 32,511 shares during the period. Rhumbline Advisers bought a new position in INmune Bio in the second quarter worth $121,000. Finally, Westside Investment Management Inc. lifted its holdings in shares of INmune Bio by 31.8% during the 2nd quarter. Westside Investment Management Inc. now owns 45,340 shares of the company’s stock worth $400,000 after acquiring an additional 10,950 shares during the period. Institutional investors own 12.72% of the company’s stock.

INmune Bio Trading Down 1.7 %

Shares of INMB stock opened at $5.85 on Friday. The stock’s fifty day simple moving average is $5.67 and its 200-day simple moving average is $7.83. The company has a market capitalization of $115.60 million, a price-to-earnings ratio of -2.84 and a beta of 1.85. INmune Bio has a 1-year low of $4.78 and a 1-year high of $14.74.

INmune Bio (NASDAQ:INMB) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.13. INmune Bio had a negative return on equity of 103.56% and a negative net margin of 26,333.59%. On average, sell-side analysts predict that INmune Bio will post -2.14 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on INMB shares. Scotiabank began coverage on INmune Bio in a report on Thursday, August 22nd. They issued a “sector outperform” rating and a $22.00 target price on the stock. Raymond James assumed coverage on shares of INmune Bio in a research note on Friday, September 27th. They set an “outperform” rating and a $18.00 price objective for the company. Finally, Alliance Global Partners initiated coverage on shares of INmune Bio in a report on Monday, October 21st. They set a “buy” rating and a $20.00 price target on the stock.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.